WuXi AppTec expands to create a center of excellence in San Diego

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/s-c-s)
(Image: Getty/s-c-s)

Related tags: Wuxi apptec, Small molecule, Manufacturing, Pharmacology, discovery services

The expansion collates WuXi AppTec’s technology platform small molecule capabilities, including screening, discovery biology, pharmacology, and process R&D.

The San Diego, CA-based facility – now a new center of excellence – also provides Phase I good manufacturing practice (GMP) manufacturing services.

WuXi AppTec​ Chairman and CEO Dr. Ge Li said the expansion will enable the company to better serve its US and global customers.

"Together with our ecosystem partners, we will continue to strengthen WuXi's capability and technology enabling platform to expedite the discovery and development of new medicines for patients worldwide,”​ Li said in a press release.

As part of the expansion, the contract research organization (CRO) also plans to hire “extensively”​ from around the San Diego area.

WuXi AppTec was unable to provide any further comment.

IPO and expansion

To build and expand its R&D facilities, the company earlier this year raised more than $353​ in an initial public offering (IPO) of common stock.

WuXi AppTec's IPO of 104,198,600 shares of common stock was offered on the Shanghai Stock Exchange at RMB21.60 per share. This, equivalent to US$3.39 per share, means the IPO has brought in more than $353m.

The company has completed expansions at several of its subsidiary companies, including STA Pharmaceutical​.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more